Page last updated: 2024-11-12

gymnemagenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gymnemagenin: isolated from Gymnema sylvestre [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GymnemagenusA plant genus of the family ASCLEPIADACEAE.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]
Gymnema sylvestrespeciesA plant species of the genus GYMNEMA that contains gymnemic acid (triterpene SAPONINS) which affects blood sugar level, and gurmarin protein. The common name of Gurmar should not be confused with Guar (CYAMOPSIS).[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]

Cross-References

ID SourceID
PubMed CID10051937
SCHEMBL ID4324523
MeSH IDM0507699

Synonyms (23)

Synonym
SCHEMBL4324523
22467-07-8
gymnemagenin
olean-12-ene-3,16,21,22,23,28-hexol, (3.beta.,4.alpha.,16.beta.,21.beta.,22.alpha.)-
gymnemagenin [usp-rs]
olean-12-ene-3.beta.,16.beta.,21.beta.,22.alpha.,23,28-hexo
U396WHT2FZ ,
gymnemagenin (constituent of gymnema) [dsc]
unii-u396wht2fz
olean-12-ene-3beta,16beta,21beta,22alpha,23,28-hexol
gymnemagenin, united states pharmacopeia (usp) reference standard
gymnemagenin, analytical standard
AKOS037515112
(3r,4r,4ar,5s,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-4a,9-bis(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-3,4,5,10-tetrol
HY-N2268
CS-0019597
Q27290632
AS-79649
gymnemagenin (usp-rs)
gymnemagenin (constituent of gymnema)
olean-12-ene-3beta,16beta,21beta,22alpha,23,28-hexo
olean-12-ene-3,16,21,22,23,28-hexol, (3beta,16beta,21beta,22alpha)-
olean-12-ene-3,16,21,22,23,28-hexol, (3beta,4alpha,16beta,21beta,22alpha)-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In present investigation, pharmacodynamics and pharmacokinetic interactions with oral hypoglycemic drug, glimepiride (GLM) was studied in streptozotocin (STZ) induced diabetic rats."( Effects of Gymnema sylvestre extract on the pharmacokinetics and pharmacodynamics of glimepiride in streptozotocin induced diabetic rats.
Duraiswamy, B; Gupta, A; Jadhav, A; Janrao, S; Kamble, B; Khatal, L; Moothedath, I, 2016
)
0.43
" Therefore, the objective of our study was to investigate the in vitro rat liver microsomal stability and caco-2 permeability along with the efflux of gymnemagenin and establish a probable correlation of these in vitro findings with pharmacokinetic parameters after oral and intravenous administration in rats."( In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study.
Adhikari, D; Bera, R; Karmakar, S; Kundu, A; Sen, T, 2016
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (88.89)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.09 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]